Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy

Breast Cancer Research and Treatment

Volumn 119, Issue 3, 2010, Pages 767-771

  Vo, M N ^a   Evans, M ^a   Leitzel, K ^a   Ali, S M ^a,b   Wilson, M ^a   Demers, L ^a   Evans, D B ^c   Lipton, A ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Biomarkers; Cancer; ELISA; Endoglin; Hormone therapy; Metastatic breast cancer; Plasma; Survival; TGF

Indexed keywords

EDETIC ACID; ENDOGLIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FADROZOLE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MEGESTROL ACETATE; MIDDLE AGED; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL;

EID: 74849096633     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0261-5     Document Type: Article

References (26)

1. NP Barbara JL Wrana M Letarte 1999 Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily J Biol Chem 274 2 584 594 10.1074/jbc.274.2.584 10.1074/jbc.274.2.584 1:CAS:528:DyaK1MXmtFGgsQ%3D%3D 9872992 (Pubitemid 29058021)
2. S Cheifetz T Bellón C Calés S Vera C Bernabeu J Massagué M Letarte 1992 Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells J Biol Chem 267 19027 19030 1:CAS:528:DyaK38Xlt1Ggurg%3D 1326540
3. R Qu MM Silver M Letarte 1998 Distribution of endoglin in early human development reveals high levels on endocardial cushion tissue mesenchyme during valve formation Cell Tissue Res 292 333 343 10.1007/s004410051064 10.1007/s004410051064 1:CAS:528:DyaK1cXitlyjsr0%3D 9560476 (Pubitemid 28230220)
4. HJ Buhring CA Muller M Letarte A Gougos A Saalmuller AJ van Agthoven FW Busch 1991 Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow Leukemia 5 841 847 1:STN:280:DyaK38%2Fnt1ensg%3D%3D 1961019
5. A Gougos M Letarte 1990 Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells J Biol Chem 265 8361 8364 1:CAS:528:DyaK3MXitVWru7Y%3D 1692830
6. A Gougos S Jacques A Greaves PJ O'Connell AJF d'Apice HJ Buhring C Bernabeu JA van Mourik M Letarte 1992 Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts Int Immunol 4 83 92 10.1093/intimm/4.1.83 10.1093/intimm/4.1.83 1:STN:280:DyaK387nt1yjug%3D%3D 1371694
7. Blann AD, Wang JM, Wilson PB, Kumar S (1996) Serum levels of TGFB receptor are increased in atherosclerosis. Atherosclerosis 120:221-226. doi: 10.1016/0021-9150(95)05713-7 (Pubitemid 26053317)
8. Li C, Guo B, Wilson PB, Stewart A, Byrne G, Bundred N, Kumar S (2000) Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 89(2):122-126. doi:10.1002/(SICI)1097-0215(20000320)89: 2<122::AID-IJC4>3.0.CO;2-M
9. N Takahashi R Kawanishi-Tabata A Haba M Tabata Y Haruta H Tsai BK Seon 2001 Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin Clin Cancer Res 7 3 524 532 1:CAS:528:DC%2BD3MXjtVOgur4%3D 11297243
10. C Li R Gardy BK Seon SE Duff S Abdalla A Renehan ST O'Dwyer N Haboubi S Kumar 2003 Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis Br J Cancer 88 9 1424 1431 10.1038/sj.bjc.6600874 10.1038/sj.bjc.6600874 1:CAS:528:DC%2BD3sXktFOgurk%3D 12778073 (Pubitemid 36606427)
11. JM Wang S Kumar D Pye AJ van Agthoven J Krupinski RD Hunter 1993 A monoclonal antibody detects heterogeneity in vascular endothelium of tumors and normal tissues Int J Cancer 54 363 370 10.1002/ijc.2910540303 10.1002/ijc.2910540303 1:STN:280:DyaK3s3osFygug%3D%3D 8509210
12. FJ Burrows EJ Derbyshire PL Tazzari, et al. 1995 Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy Clin Cancer Res 1 1623 1634 1:CAS:528:DyaK28XmvVWgsg%3D%3D 9815965
13. DY Li LK Sorensen BS Brooke, et al. 1999 Defective angiogenesis in mice lacking endoglin Science 284 1534 1537 10.1126/science.284.5419.1534 10.1126/science.284.5419.1534 1:CAS:528:DyaK1MXjs1WhsrY%3D 10348742 (Pubitemid 29291401)
14. MJ Beresford AL Harris M Ah-See F Daley AR Padhani A Makris 2006 The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer Br J Cancer 95 1683 1688 10.1038/sj.bjc.6603491 10.1038/sj.bjc.6603491 1:CAS:528:DC%2BD28Xht12ktbfK 17160082 (Pubitemid 44950794)
15. S Kumar A Ghellal C Li G Byrne N Haboubi JM Wang N Bundred 1999 Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis Cancer Res 59 856 861 1:CAS:528:DyaK1MXht1Sis7s%3D 10029075
16. JP Dales S Garcia P Bonnier F Duffaud L Andrac-Meyer O Ramuz MN Lavaut C Allasia C Charpin 2003 CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas: correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients Am J Clin Pathol 119 3 374 380 10.1309/1KF54L6RB625556W 10.1309/1KF54L6RB625556W 12645339 (Pubitemid 37047860)
17. JP Dales S Garcia S Carpentier L Andrac O Ramuz MN Lavaut C Allasia P Bonnier C Taranger-Charpin 2004 Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n = 905) Br J Cancer 90 1216 1221 10.1038/sj.bjc.6601452 10.1038/sj.bjc.6601452 1:CAS:528:DC%2BD2cXitV2rsrs%3D 15026804 (Pubitemid 38496816)
18. Buzdar AU, Smith R, Vogel C et al (1996) Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer 77:2503-2513. doi:10.1002/(SICI)1097- 0142(19960615)77:12<2503::AID-CNCR13>3.0.CO;2-W (Pubitemid 26169147)
19. A Lipton SM Ali K Leitzel L Demers V Chinchili L Engle C Brady CM Nalin M Dugan W Carney J Allard 2002 Elevated serum Her-2/Neu level predicts decreased response to hormone therapy in metastatic breast cancer J Clin Oncol 20 1467 1472 10.1200/JCO.20.6.1467 10.1200/JCO.20.6.1467 1:CAS:528:DC%2BD38XivFeisbk%3D 11896093 (Pubitemid 34260524)
20. CG Li PB Wilson C Bernabeu U Raab JM Wang S Kumar 1998 Immunodetection and characterization of soluble CD105-TGF β complexes J Immunol Methods 218 85 93 10.1016/S0022-1759(98)00118-5 10.1016/S0022-1759(98)00118-5 1:CAS:528:DyaK1cXnt12hsr4%3D 9819125 (Pubitemid 28500135)
21. Li C, Guo B, Bernabeu C, Kumar S (2001) Angiogenesis in breast cancer: the role of transforming growth factor β and CD105. Microsc Res Tech 52(4):437-449. doi:10.1002/1097-0029(20010215)52:4<437::AID-JEMT1029>3.0. CO;2-G (Pubitemid 32167832)
22. JL Moody S Singbrant G Karlsson U Blank M Aspling J Flygare D Bryder S Karlsson 2007 Endoglin is not critical for hematopoietic stem cell engraftment and reconstitution but regulates adult erythroid development Stem Cells 25 11 2809 2819 10.1634/stemcells.2006-0602 10.1634/stemcells.2006-0602 1:CAS:528:DC%2BD2sXhtl2gsLnI 17673527 (Pubitemid 350127865)
23. JA Karam RS Svatek PI Karakiewicz A Gallina CG Roehrborn KM Slawin SF Shariat 2008 Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer Clin Cancer Res 14 1418 1422 10.1158/1078-0432.CCR-07-0901 10.1158/1078-0432.CCR-07-0901 1:CAS:528:DC%2BD1cXislSrsLw%3D 18316564
24. Sarmiento R, Franceschini R, Meo S, Gion M, Longo R, Gasparini G (2006) Circulating vascular endothelial growth factor. In: Gasparini G, Hayes DF (eds) Biomarkers in breast cancer. Humana Press, Totowa, NJ
25. D Oxmann J Held-Feindt AM Stark K Hatterman T Yoneda R Mentlein 2008 Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype Oncogene 27 2567 2575 10.1038/sj.onc.1211025 10.1038/sj.onc.1211025 (Pubitemid 351793804)
26. NA Dallas S Samuel L Xia F Fan MJ Gray SJ Lim LM Ellis 2008 Endoglin (CD 105): a marker of tumor vasculature and potential target of therapy Clin Cancer Res 14 1931 1937 10.1158/1078-0432.CCR-07-4478 10.1158/1078-0432.CCR-07-4478 1:CAS:528:DC%2BD1cXkt1aktbs%3D 18381930 (Pubitemid 351551101)